SUPN vs QURE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SUPN · Supernus Pharmaceuticals$26.16 ▼ 2.17%
QURE · uniQure NV$21.70 ▲ 3.28%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SUPN -42.4%
- QURE -17.0%
Head to head
| Metric | SUPN | QURE |
|---|---|---|
| Price | $26.16 | $21.70 |
| Change today | ▼ 2.17% | ▲ 3.28% |
| Market cap | $1.52B | $1.52B |
| Return, 3 months | -44.4% | -52.9% |
| Return, year to date | -47.4% | -9.3% |
| Return, 1 year | -43.2% | -21.9% |
| P/E (TTM) | – | – |
| P/B | 1.4 | 5.2 |
| P/E percentile vs own 5y | 20th | 28th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +18.0% | +11.0% |
| Net profit growth (YoY) | +146.4% | -114.9% |
| Gross margin | 87.6% | 92.5% |
| Operating margin | 3.2% | -1,020.8% |
| Net margin | -5.1% | -1,350.7% |
| Return on equity | -4.2% | -157.6% |
| Analyst target vs. price | +129.4% | +138.1% |
| Analyst buy share | 67% | 78% |
| RSI (14) | 21 | 36 |
| 30-day volatility | 125.6% | 149.0% |
| Max drawdown, 1 year | -54.1% | -87.2% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SUPN is the largest of the group by market value.
- QURE has returned the most over the past year.
- SUPN is growing revenue fastest.
- SUPN keeps the most profit per dollar of sales.
- SUPN has been the calmest stock over the last 30 days.